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Abstract
Background: Routes of transmission of hepatitis B virus (HBV)/
HIV infections are similar and there is a significant rate of co-in-
fection in patients. A study was recently carried out in NHS Fife, 
Scotland  from  February  2007  -  February  2008  to  estimate  the 
prevalence of HBV/HIV co-infection, occult HBV infection and 
immunisation status against HBV in a cohort of patients with HIV 
attending the departments of infectious diseases and genitourinary 
medicine.
Methods: Case notes were reviewed retrospectively (n = 70). De-
tails  on  patient  demographics,  risk  category,  nadir/current  CD4 
count, HIV viral load and vaccination history were analysed. HBV 
markers  (HBsAg/anti-HBs/anti-HBc/HBV  DNA)  and  alanine 
transaminase (ALT) levels were tested prospectively if these tests 
had not been carried out in the previous 12 months.
Results and conclusions: Prevalence of HBV/HIV co-infection 
was 5.6% of which 2.8% of patients had occult infection and 22.9% 
had evidence of previous exposure. Although HBV is preventable 
by vaccination, only 24.2% of patients had been vaccinated against 
it. Improvements could therefore be made in the field of preven-
tion with vaccination and monitoring the immune response in this 
cohort.
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Introduction
There are estimated 350 million hepatitis B virus (HBV) car-
riers and around 40 million HIV infected patients worldwide 
[1, 2]. Routes of transmission for these two infections are 
similar and there is a significant rate of co-infection in pa-
tients. Underlying HIV infection decreases the rate of HBV 
clearance, and increases the chance of HBV chronicity and 
progression [3, 4]. British HIV Association (BHIVA) guide-
lines therefore recommend that all HIV infected individuals 
should be tested for HBV serum markers, in part to deter-
mine which individuals should receive vaccination against 
this virus [5].
There is no comprehensive data from the UK defining 
HIV/HBV co-infection rates. A study in 631 HIV positive 
people, most of whom were homosexual men, in London 
showed a dual HIV/HBV infection rate of 6% [6]. In many 
parts  of  Africa,  HIV/HBV  co-infection  is  common,  and 
therefore high infection rates are to be expected in recent 
immigrants  from Africa.  High  rates  of  co-infection  with 
HBV and also hepatitis C virus (HCV) are expected amongst 
HIV positive injecting drug users. For patients with HIV/
HCV co-infection, prevention of HBV infection is critical, 
because this viral infection can be particularly severe and 
may adversely affect therapy for HIV infection [7].
We therefore carried out a study on all HIV patients at-
tending the blood borne virus clinics and genitourinary clin-
ics in Fife, Scotland to determine the: 1) prevalence of HBV 
infection in Fife HIV cohort; 2) prevalence of occult HBV 
infection; 3) immunisation status for HBV in the Fife HIV 
cohort.
 
Materials and Methods
Case notes on all HIV patients attending the blood borne 
virus and genitourinary clinics in NHS Fife from February 
2007 to February 2008 were reviewed retrospectively. NHS 
Fife serves a population of approximately 280 000. Details 
on patient demographics, risk category for HIV/HBV ac-
quisition, nadir/current CD4 count, HIV viral load and time 
Manuscript accepted for publication December 2, 2009
aInfectious Diseases Unit, Victoria Hospital (NHS Fife), Kirkcaldy, Fife, 
  Scotland, UK
bGenitourinary Medicine, The Beeches Centre, Forth Park Hospital, 
  Kirkcaldy, Fife, Scotland, UK
cCorresponding author: lukman.hakeem@faht.scot.nhs.uk
doi:10.4021/jocmr2009.12.1282
 34                                                                                                                                                   35J Clin Med Res  •  2010;2(1):34-38 Hakeem et al
Articles © The authors, Journal compilation © J Clin Med Res and Elmer Press™, www.jocmr.org
since diagnosis of HIV were recorded. HBV serum markers 
including hepatitis B surface antigen (HBsAg), hepatitis B 
surface antibody (anti-HBs) and hepatitis B core IgG anti-
body (anti-HBc), and Hepatitis C markers including hepatitis 
C antibody and polymerase chain reaction (PCR) for anti-
body positive patients were tested prospectively if these tests 
were not carried out in the previous 12 months. Patients with 
a positive HBsAg result and patients with positive anti-HBc 
result underwent further testing for HBV DNA by PCR. Ala-
nine transaminase (ALT) levels were also recoded during the 
time of testing HBV serum markers. ALT levels were consid-
ered to be normal if it was less than 40 IU/ml, mildly raised 
if it was less than twice normal levels or raised if it was more 
than twice normal levels. HBV vaccination history was ob-
tained from case notes or from direct questioning of patients. 
Details of anti retroviral medications were obtained from 
case notes. A total of 70 patients were included in the study; 
8 patients were excluded as they had moved away from Fife 
before all the HBV markers were tested. Continuous vari-
ables are presented as mean values and absolute variables are 
presented as percentages.
 
Results
Male to female ratio was 2.3 to 1 (49 males, 21 females). 
Mean age was 42.6 years (range 20 - 69). Patient ethnic-
ity consisted of 55 (78%) Caucasians, 12 (17%) Africans, 
and 4 (5%) Asians. Main risk factors for acquiring HIV in 
this cohort were as follows: 40 patients (57%) acquired HIV 
by heterosexual contact, 22 (31%) through same sex contact 
(MSM) and 8 (12%) patients acquired HIV through intra-
venous drug use. Mean time since diagnosis of HIV was 6 
years (1 month - 20 years). Patient variables are shown in 
Table 1.
Table 2 breaks down the vaccination figures further: 9 
of 22 patients (41%) who acquired HBV through same sex 
contact (MSM) were vaccinated; 7 patients (78%) had de-
tectable antibody response, with 5 patients (56%) demon-
strating sufficient antibody response (> 100 IU/ml) accord-
ing to BHIVA guidelines; 8 of 48 patients (17%) of other risk 
groups were vaccinated; 5 patients (62.5%) had a detectable 
antibody response, with 2 patients (25%) demonstrating an 
antibody response of more than 100 IU/ml.
Table 1. Variables of HIV Cohort in Fife
Category Vaccination Status Antibody Response
> 100 IU/l        < 100 IU/l       Not tested     
MSM
n = 22 (31%)
Vaccinated: 9 (41%)         
Not vaccinated: 13 (59%) 
5 (56%)            2 (22%)           2 (22%)
Others
n = 48 (69%)
Vaccinated: 8 (17%)
Not vaccinated: 40 (83%)
2 (25%)            3 (37.5)           3 (37.5%)
Table 2. HBV Vaccination Status and Antibody Response in the HIV Cohort in Fife
Characteristic of Variable Results
Age in years: 
Mean (range)
42.6 (20 - 46)
Nadir CD4: 
Mean (range) cells/mm3
174 (0 - 673)
CD4 cell count at the time of HBV testing:
Mean (range) cells/mm3 
409 (52 - 1074)
HIV RNA level at the time of HBV testing:
Mean (range) copies/ml 
29012 
(< 40 - 1000000)
HCV antibody positivity 9 (12.9%)
HCV RNA positivity 8 (11.2 %)
Current HBV infection/carrier
(HBsAg positive, anti-HBc positive)
2 (2.8%)
Past exposure to HBV
(HBsAg negative, anti-HBc positive)
16 (22.9%)
Occult HBV infection
(HBsAg negative, anti-HBc positive, 
HBV DNA positive)
2 (2.8%)
Positive history for HBV immunisation 17 (24.2%)
Detectable Anti-HBs in immunised patients 12 (70.6%)
ALT level on HBsAg positive, anti-HBc 
positive patients: Mean (range) IU/ml
32.6 (10 - 111)
Patients with positive HBV serum markers 
currently receiving TDF/3TC/FTC regimes
14 (77.8%)
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Discussion
  
Hepatitis B is one of the most common human pathogens 
worldwide. Although hepatitis B is a double-stranded DNA 
virus, it has several common features with HIV. After enter-
ing the hepatocyte, viral DNA is integrated into the host ge-
nome. Viral RNA is translated by HBV reverse polymerase 
into viral DNA and transcribed into viral proteins. Reverse 
transcription may be inhibited by nucleotides reverse tran-
scriptase inhibitors. Integration of the virus into the host ge-
nome of hepatocytes and CD4+ T-cells prevents its eradica-
tion. Finally, the mechanisms for development of resistance 
are very similar for both viruses.
There is considerable variation of HBV/HIV co-infec-
tion among geographical regions and risk groups. Our study 
showed that 25.7% of HIV patients had evidence of exposure 
to HBV (anti-HBc positive) with 2.8% currently co-infected 
(HBsAg  positive,  anti-HBc  positive)  and  22.9%  showing 
evidence of past exposure (HBsAg negative, anti-HBc posi-
tive). The combination of HBsAg negativity and anti-HBc 
positivity is traditionally interpreted as indication of prior 
hepatitis B infection with clearance. More recently, it has be-
come apparent that HBV DNA can be detected in the serum 
from at least some individuals who exhibit this combination 
[8]. The term occult infection is used to describe this picture. 
Among our patients, 2.8 % had a detectable HBV DNA and 
anti-HBc despite a negative HBsAg, thus fulfilling the crite-
ria for an occult infection.
Studies indicate that the natural history of HBV is al-
tered in patients with HIV disease due to immune dysfunc-
tion which increases the risk of becoming a chronic HBV 
carrier [9]. During HIV infection, an isolated anti-HBc can 
be validly interpreted as immunity with past infection, false 
positive core antibody, late phase of an acute HBV infec-
tion when HBsAg has disappeared or chronic HBV infection 
with an undetectable HBsAg or a low level of HBsAg titre. 
However, it is unlikely for the anti-HBc to be falsely positive 
in high risk persons [10]. Furthermore, in a recent long term 
follow-up study of anti-HBc/HIV positive patients of whom 
transient HBsAg positivity developed in 24%, HBV DNA 
became positive in 60% and about a third of these patients 
had  active  liver  disease,  thus  suggesting  that  an  isolated 
anti-HBc most likely represents chronic infection [11]. It is 
therefore vital to test for anti-HBc in patients with negative 
HBsAg in HIV disease, partly to determine which patients 
would be likely to develop occult infection or reactivation of 
HBV. Also, HBV markers including HBV DNA (in anti-HBc 
positive patients) should be rechecked annually, especially if 
the liver function tests become abnormal.
In patients requiring HIV therapy who are HBsAg posi-
tive, therapy would normally include tenofovir (TDF), or a 
combination of tenofovir with either lamivudine (3TC) or 
emtricitabine (FTC) as part of, or in addition to, their anti-
retroviral regimen [5]. Withdrawal of lamivudine may result 
in an acute exacerbation of hepatitis that may be sufficient 
to precipitate liver decompensation [12, 13]. There are also 
reports of clinical reactivation of HBV infection in HIV in-
fected patients with isolated anti-HBc as the only serological 
marker after lamivudine withdrawal [14]. This study showed 
that 77.8% of HIV patients in Fife who had a positive anti-
HBc result were on TDF, TDF/FTC or 3TC containing regi-
mens. In this group, all patients with a positive HBsAg or 
HBV DNA in addition to anti-HBc indicating current infec-
tion or occult infection were on appropriate anti-retroviral 
therapy. Rest of the patients with a positive anti-HBc, but not 
on any anti-retroviral therapy had good CD4 count results (> 
500 cells/mm3). BHIVA guidelines recommend that patients 
who are HBV/HIV co-infected, with a CD4 count less than 
500 cells/mm3 should commence HAART. Only exception 
to this may be the patient with a CD4 count 350 - 500 cells/
mm3, HBV DNA less than 2000 IU/ml with normal ALT lev-
els and no evidence of fibrosis or hepatic inflammation. In 
this situation, close monitoring is essential [5].
HBV is immunopathic (the immune response to the virus 
causes most of the liver damage) and therefore in HIV infec-
tion there is often a decrease in the serum transaminases and 
a decrease in the histological inflammatory indices. Mean 
ALT level amongst our patients with a positive HBsAg or 
anti-HBc was 32.6 IU/ml which is within the normal range. 
It is therefore important to test for HBV in HIV disease even 
if the liver enzymes are not elevated. However, co-infection 
with HIV is usually accompanied by an increase in HBV rep-
lication [15, 16], and at very high levels of viral replication 
the virus may have a direct cytopathic effect.
In HIV infected patients, chronic HBV has an unfavour-
able course compared with those who do not, and the risk of 
liver-associated mortality is significantly increased. In addi-
tion to increased mortality, HIV co-infection accelerates the 
progression of hepatitis B and increases the risk of cirrhosis. 
Therefore, prevention is vital and HBV infection is prevent-
able by vaccination. HIV positive patients however respond 
less well to vaccine, especially when the CD4 count is low. 
Also, protective antibodies are lost more quickly [17]. Some 
authors  therefore  recommend  a  conventional  vaccination 
dose for patients with CD4 counts of more than 500 cells/
mm3 (20µg at months 0, 1 and 12), and an intensive sched-
ule for patients with CD4 counts of less than 500 cells/mm3 
(20µg at months 0, 1, 2 and the last dose between months 
6 and 12) [17]. Double dose vaccine may also improve re-
sponse rates. However, if the CD4 cell count is less than 200 
cells/mm3, the patients should receive antiretroviral therapy 
first and immunisation thereafter [5]. Our study showed that 
24.2% of patients were vaccinated for HBV. Table 2 shows 
the breakdown figures clearly. Recently published Quality 
improvement Scotland (QIS) standards recommend that at 
least 70% of all MSM who are attending sexual health ser-
vices and not known to be immune to HBV should receive at 
least one dose of HBV vaccine [18]. Only 41% of our MSM 
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were vaccinated and only 56% of these patients had a suf-
ficient antibody response of more than 100 IU/ml (BHIVA 
standards). Vaccination figures fall well short for other risk 
groups with only 17% being vaccinated with 25% showing 
a  sufficient  antibody  response.  Therefore,  improvements 
could be made in the field of prevention with vaccination 
and monitoring the immune response in our patients. 
In conclusion, the prevalence of HBV infection in the 
Fife HIV cohort is 5.6% of which 2.8% of patients had evi-
dence of occult infection. Furthermore, 22.9% of patients 
had evidence of previous exposure to HBV and were at risk 
of reactivation. Although HBV is preventable by vaccina-
tion, only a minority (24.2%) of patients had been vacci-
nated against it.
We therefore recommend adopting the following steps 
from recently updated BHIVA guidelines [5] on co-infection 
with HIV and HBV infection during assessment and man-
agement of all HIV positive patients: 1) all patients should 
have  serum  markers  for  HBV  (HBsAg,  anti-HBc  and/or 
anti-HBs) checked within a month of diagnosis and should 
have further tests if the result is positive; 2) all those nega-
tive ones for HBV markers should be immunised and anti-
HBs checked at 6 - 8 weeks post vaccination (ART naive 
patients with a CD4 count of less than 200 cells/mm3 should 
receive combination therapy first and with immune recov-
ery,  immunisation  subsequently);  3)  following  successful 
immunisation, anti-HBs levels should be checked yearly and 
booster doses of vaccine should be given to those with anti-
HBs level of less than 100 IU/l; 4) persons who fail to sero-
convert to HBV vaccine and are at continuing risk of HBV 
infection should have annual HBV markers performed ( HB-
sAg and anti-HBc); 5) all patients who are anti-HBc positive 
but HBsAg negative are at risk of HBV reactivation, thus 
HBV markers including HBV DNA should be rechecked 
annually or if the liver function tests become abnormal; 6) 
decisions on appropriate ART combinations should be made 
after the results of HBV markers.
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